Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19

Diana F. Florescu and Andre C. Kalil

Purpose of review
Janus Kinase (JAK) inhibitors have been successfully utilized in the clinical treatment of several rheumatologic (e.g. rheumatoid arthritis) and inflammatory diseases (e.g. hemophagocytic lymphohistiocytosis). Based on the growing evidence that moderate and severe COVID-19 infections are associated with a dysregulated inflammatory state, this class of medications has been repurposed as a potential therapy for COVID-19, an infection caused by Severe Acute Respiratory Syndrome Coronavirus 2.

Recent findings
Three JAK inhibitors have been evaluated in human studies of COVID-19: Baricitinib, Tofacitinib, and Ruxolitinib. Most published studies are observational, but three randomized placebo-controlled double-blind trials have been completed: two large trials (N = 2,558 patients) with baricitinib demonstrated significant faster improvement in clinical status and reduction in the recovery time, as well as, significant reduction in the progression to invasive mechanical ventilation and mortality. One smaller randomized trial (N = 289) involving tofacitinib showed significant reduction in the progression to invasive ventilation or death. Notably, these three randomized placebo-controlled trials with close to 3,000 patients did not reveal any safety concerns associated with JAK inhibitors in terms of secondary infections or venous thromboembolism. Based on this high-quality evidence, both the Infectious Diseases Society of America and the National Institutes of Health guidelines recommend using baricitinib as part of the treatment approach for hospitalized patients with COVID-19.

Summary
JAK inhibitors are novel treatment agents in the field of infectious diseases. One JAK inhibitor, baricitinib has demonstrated significant clinical and survival benefits in hospitalized patients with COVID-19 in phase III randomized placebo-controlled trials. Baricitinib is already recommended for clinical practice by multiple guidelines.

Keywords
baricitinib, COVID-19, Janus Kinases inhibitors, ruxolitinib, tofacitinib

INTRODUCTION
Janus Kinases (JAK) are cytoplasmatic kinases and transmembrane proteins normally expressed in most cells that participate in the signaling of a broad range of cell surface receptors and play a role in the mediation and amplification of extracellular signals from cytokines and growth factors [1]. A large number of cytokines are dependent on JAK1, including IL-2, IL-4, IL-7, IL-9, IL-15, IL-21, and JAK 1 is also relevant for the family that uses the shared receptor gp130, including IL-6, IL-11, oncostatin M, leukemia inhibitory factor, ciliary neutrophilic factor, and granulocyte colony-stimulating factor [2].

Patients who progress to a moderate to severe form of COVID-19 and require hospitalization are more likely to develop a dysregulated immunological response that is associated with abnormal inflammatory and coagulation responses, resembling a cytokine release syndrome [3–7].

JAK inhibitors are targeted synthetic drugs that inhibiting primarily JAK1 and/or JAK2 receptors. These drugs can modulate the immunological and inflammatory abnormal responses associated with COVID-19 [8]. Among the seven JAK inhibitors that have been developed (baricitinib, tofacitinib, ruxolitinib, peficitinib, decernotinib, upadacitinib, and...
Immunomodulation treatment with several JAK inhibitors has already been evaluated in observational and randomized studies in patients with COVID-19. One JAK inhibitor, baricitinib has already demonstrated significant clinical and survival benefits in hospitalized patients with COVID-19. JAK inhibitors are novel therapeutic agents in the field of infectious diseases.

BARICITINIB

Baricitinib inhibits the signaling of multiple cytokines related to JAK-1 and 2 receptors, and has been approved for the treatment of moderate to severe rheumatoid arthritis and psoriatic arthritis based on a large randomized controlled trial [9]. In the search for known and approved drugs as potential therapies against COVID-19, artificial intelligence studies suggested that baricitinib could be potentially beneficial [10,11]. In addition to its immunomodulating properties, artificial intelligence algorithms predicted that baricitinib could inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by reducing the AP-2 mediated viral propagation, which would suggest a direct antiviral activity.

Both published observational and clinical trial data suggest a benefit of baricitinib for the treatment of COVID-19. Five observational studies showed that baricitinib was associated with a more rapid decrease of inflammatory markers, faster clinical improvement, better respiratory status, less need of intensive care, and lower mortality [12,13–16]. Two randomized, placebo-controlled, double-blind trials evaluating the effect of baricitinib therapy in hospitalized patients with COVID-19 have also been performed [17,18]. The first trial by Kalil et al. [17], enrolled 1033 patients and compared baricitinib plus remdesivir versus baricitinib plus placebo; this trial demonstrated that baricitinib plus remdesivir was superior in reducing recovery time (RR = 1.16, 95% CI 1.01–1.32), particularly in patients receiving high-flow or noninvasive ventilation (1.51 95% CI 1.10–2.08), and accelerating improvement in clinical status (OR = 1.3, 95% CI 1.0–1.6) in hospitalized patients with COVID-19; additionally, the combination was associated with a significant reduction in the new use of oxygen from 40% to 23%, significant reduction of new use of mechanical ventilation from 15% to 10%, a significant 31% reduction in the progression to invasive ventilation or death (0.69 95% CI 0.50–0.95), and 11 days less on mechanical ventilation compared to placebo (see Table 1). Notably, the baricitinib/remdesivir combination was associated with significantly less serious adverse events (16% versus 21%; P = 0.03), and lower rate of new infections (5.9% versus 11.2%; P = 0.003) compared to placebo. The second trial by Marconi et al. [18], enrolled 1525 patients, and compared baricitinib plus standard of care versus standard of care. Although the primary endpoint – a reduction of disease progression – was not achieved, a significant relative mortality reduction was demonstrated with baricitinib compared to placebo (HR = 0.57, 95% CI 0.41–0.78, P = 0.0018). This survival benefit with baricitinib was independent of the use of steroids or remdesivir. Baricitinib has not been evaluated in combination with other immunomodulators such as IL-6 antagonists, but

| Table 1. Published studies: mortality and invasive mechanical ventilation outcomes |
|-----------------|---------------|--------------------------------|------------------|
| **JAK inhibitor** | **Number of observational studies** | **Number of randomized trials** | **28-day mortality hazard ratio** |
| BARICITINIB | 5 | 2 | Overall: 0.65 (95% CI 0.39–1.09) |
| | | | Low/High-flow: 0.47 (95%CI 0.24–0.93) |
| | | | Overall: 0.57 (95% CI 0.41–0.78) |
| TOFACITINIB | 2 | 1 | 0.49 (95% CI 0.15–1.63) |
| RUXOLITINIB | 8 | 1 | Not Available |

Kalil et al. [1], Marconi et al. [2], Guimaraes et al. [3].
1. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021; 384(9):795-807.
2. Marconi VC, Ramonan AV, deBono S., et al. Baricitinib plus standard of care for hospitalized adults with COVID-19. medRxiv preprint doi: https://doi.org/101101/2021043021255934. 2021.
3. Guimaraes PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021.
considering the potential additional immunosuppression, these combinations will need to be evaluated in randomized controlled trials to determine safety and efficacy. The safety profile was similar between baricitinib and placebo despite the fact that most patients also received steroids. Importantly, both randomized trials above did not show differences in venous thromboembolic events between the treatment and control arms, assuaging concerns that baricitinib treatment could be thrombogenic.

TOFACITINIB

Two observational studies [19,20], and one randomized placebo-controlled double-blind trial [21**] have evaluated the use of tofacitinib in hospitalized patients with COVID-19. Both observational trials suggested a better clinical response with tofacitinib. The randomized trial enrolled 289 patients, and showed that tofacitinib was associated with a significant lower risk of death or respiratory failure at day 28 (RR = 0.63, 95% CI 0.41–0.97) compared to placebo. Also, no safety differences, including rates of secondary infections and thromboembolic events, were noted between treatment and control arm. Several ongoing trials are evaluating tofacitinib and expected to be completed soon.

RUXOLITINIB

There are several observational studies already published regarding the use of ruxolitinib in patients with COVID-19 [22–29], and these case reports and case series suggest improvement of pulmonary function and hospital discharge with ruxolitinib. One small randomized single-blind controlled trial which enrolled 43 patients was performed by Cao et al. [30]; this study suggested a faster clinical and tomographic improvement, and a numerically lower mortality with ruxolitinib, and differences were not significant. Trials on ruxolitinib are ongoing, thus more information will further clarify the potential role of this drug in patients with COVID-19.

CONCLUSION

JAK inhibitors have been successfully utilized in the clinical treatment of several rheumatologic (e.g. rheumatoid arthritis) and inflammatory diseases (e.g. hemophagocytic lymphohistiocytosis). Based on the growing evidence that moderate and severe COVID-19 infections are associated with a dysregulated inflammatory state, this class of medications has been repurposed as a potential therapy for COVID-19, an infection caused by SARS-CoV-2. Three JAK inhibitors have been evaluated in human studies of COVID-19: Baricitinib, Tofacitinib, and Ruxolitinib. Most published studies are observational, but three randomized placebo-controlled double-blind trials have been completed: two large trials (N = 2,558 patients) with baricitinib demonstrated significant faster improvement in clinical status and reduction in the recovery time, as well as, significant reduction in the progression to invasive mechanical ventilation and mortality. One smaller randomized trial (N = 289) involving tofacitinib showed significant reduction in the progression to invasive ventilation or death. Notably, these three randomized placebo-controlled trials with close to 3,000 patients did not reveal any safety concerns associated with JAK inhibitors in terms of secondary infections or venous thromboembolism. Based on this high-quality evidence, both the Infectious Diseases Society of America [31] and the National Institutes of Health [32] guidelines recommend using baricitinib as part of the treatment approach for hospitalized patients with COVID-19.

Acknowledgements

None.

Financial support and sponsorship

No financial support for this study.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as: ■ of special interest ■■ of outstanding interest

1. Bertsias G. Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors. Medit J Rheumatol 2020; 31(Suppl 1):105–111.
2. Yamaoka K, Saharinen P, Pesu M, et al. The Janus kinases (Jaks). Genome Biol 2004; 5:253.
3. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033–1034.
4. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130:2620–2629.
5. McGinnage D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020; 19:102537.
6. Wan S, Yi Q, Fan S, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol 2020; 189:428–437.
7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506.
8. Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol 2020; 2:e428–e436.
9. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017; 376:652–662.
10. Stiebing J, Krishnan V, de Bono S, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med 2020; 12:e12697. This study provides support for the mechanism of action of baricitinib as a potential anti-SARS-CoV-2 treatment.
Severe infections

11. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020; 395:e30–e31.
12. Tita Jr BK, Farley MM, Mehta A, et al. Use of baricitinib in patients with severe to moderate coronavirus disease 2019. Clin Infect Dis 2021; 72:1247–1250.

This report shows the reduction in inflammatory markers and improved clinical symptoms with baricitinib in a case series.

13. Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect 2020; 81:318–356.
14. Cantini F, Niccoli L, Nannini C, et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect 2020; 81:647–676.
15. Abizanda P, Calbo Mayo JM, Mas Romero M, et al. Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia. J Am Geriatr Soc 2021.
16. Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, et al. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rheumatology 2021; 60:399–407.
17. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021; 384:795–807.

This is the first randomized placebo-controlled double-blind trial to show baricitinib to be associated with significant faster clinical recovery and lower progression to invasive mechanical ventilation or death in hospitalized patients with COVID-19.

18. Marconi VC, Ramanan AV, deBono S, et al. Baricitinib plus standard of care for hospitalized adults with COVID-19. medRxiv 2021. preprint doi: https://doi.org/10.1101/2021.04.30.21255934.

This is a large randomized placebo-controlled double-blind trial that demonstrated that baricitinib is associated with a significant mortality reduction in hospitalized patients with COVID-19.

19. Masielennik R, Ivashkin V, Vasilieva E, et al. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19. Pulm Pharmacol Ther 2021; 69:102039.
20. Hayek ME, Mansour M, Nidelan H, et al. Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in: a predominantly African American Cohort. Mayo Clin Proc Innov Qual Outcomes 2021; 5:605–613.

21. Guimaraes PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021. This randomized placebo-controlled trial showed a significant reduction in mechanical ventilation or death with tofacitinib in hospitalized patients with COVID-19.
22. Capociani E, Frediani B, Iervasi G, et al. Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease. analysis of data collection from RESPIRE protocol. Front Med 2020; 7:466.
23. Innes AJ, Cook LB, Marks S, et al. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection. Br J Haematol 2020; 180:e198–e200.
24. Kaplanski G, Bontemps D, Esnault P, et al. Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: a pilot study. Autoimmun Rev 2021; 20:102726.
25. Koschmieder S, Jost E, Cornelissen C, et al. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis. Eur J Haematol 2020; 105:655–658.
26. Sammartano V, Santoni A, Frediani B, et al Efficacy and safety of ruxolitinib for COVID-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant). Leuk Lymphoma 2020; 61:3523–3525.
27. Saraceni F, Scortechini I, Mancini G, et al. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib. Transpl Infect Dis 2021; 23:e13401.
28. Sarmiento M, Rojas P, Jerez J, et al. Ruxolitinib for severe COVID-19-related hyperinflammation in nonresponders to steroids. Acta Haematol 2021; 1–7.
29. Vannuccini AM, Sordi B, Moretti A, et al. Compassionate use of Jak1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia 2021; 35:1121–1133.
30. Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 2020; 146:137–146, e3.
31. IDSA Guideline on the treatment and management of patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. 2021.
32. NIH COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/. 2021.